0001209191-21-049123.txt : 20210802
0001209191-21-049123.hdr.sgml : 20210802
20210802192735
ACCESSION NUMBER: 0001209191-21-049123
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210729
FILED AS OF DATE: 20210802
DATE AS OF CHANGE: 20210802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Imran Talat
CENTRAL INDEX KEY: 0001869579
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40672
FILM NUMBER: 211137386
MAIL ADDRESS:
STREET 1: C/O RANI THERAPEUTICS HOLDINGS, INC.
STREET 2: 2051 RINGWOOD AVENUE
CITY: SAN JOSE
STATE: CA
ZIP: 95131
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Rani Therapeutics Holdings, Inc.
CENTRAL INDEX KEY: 0001856725
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2051 RINGWOOD AVENUE
CITY: SAN JOSE
STATE: CA
ZIP: 95131
BUSINESS PHONE: (408) 457-3700
MAIL ADDRESS:
STREET 1: 2051 RINGWOOD AVENUE
CITY: SAN JOSE
STATE: CA
ZIP: 95131
3/A
1
doc3a.xml
FORM 3/A SUBMISSION
X0206
3/A
2021-07-29
2021-07-29
0
0001856725
Rani Therapeutics Holdings, Inc.
RANI
0001869579
Imran Talat
C/O RANI THERAPEUTICS LLC
2051 RINGWOOD AVE.
SAN JOSE
CA
95131
1
1
0
0
Chief Executive Officer
Class A Common Stock
829435
I
See footnote
Class A Common LLC Units
Class A Common Stock
43421
D
Stock Option (Right to Buy)
9.45
2031-07-28
Class A Common Stock
78877
D
This amendment is being filed to correctly reflect the shares held directly and indirectly.
Represents 378,533 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 450,902 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
Represents Class A Common LLC Units of Rani Therapeutics, LLC, a direct subsidiary of the Issuer. The Class A Common LLC Units are exchangeable for shares of Class A Common Stock on a one-for-one basis at the discretion of the holder, subject to certain exceptions, conditions and adjustments, and have no expiration date.
The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from June 17, 2021.
This amendment is being filed to correctly reflect the exercise price of the Stock Option.
/s/ Josh Seidenfeld, Attorney-in-Fact for Talat Imran
2021-08-02